US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-22 03:43:06 Source:healthViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
You may also like
- Four people killed in a house explosion in southwestern Missouri
- Chris Pratt divides fans as he publicly snubs ex
- James Gregory dead at 78: Stand
- Georgian parliament holds third and final reading of divisive bill on foreign influence
- Xander Schauffele gets validation and records with one memorable putt at PGA Championship
- Migration tracking group says 76 million people were displaced within their countries in 2023
- A French court clears director Roman Polanski of defaming a British actor
- Jaden Smith and his model girlfriend Sab Zada match in hoodies and trainers for a casual date night
- Israeli army says it kills over 130 militants in E. Rafah